Terrasil Ringworm Anti-fungal Cleansing Bar 75g

Dosage for Thuja Occidentalis Whole is highly individualized and is never 'one-size-fits-all.' The dosage is determined by the patient's level of sensitivity and the method of administration.

Diagnostic Testing Dosage

• Skin Prick (Epicutaneous) Test: A single drop of the 1:10 or 1:20 w/v concentrate is applied to the skin (usually the forearm or back), and the skin is pricked through the drop. This represents a minute exposure.
• Intradermal Test: If the prick test is negative, a much smaller volume (typically 0.02 mL to 0.05 mL) of a 1:1000 or 1:500 w/v dilution is injected into the dermis.

Immunotherapy Dosage

• Build-up Phase: Treatment usually begins with a very low dose (e.g., 0.05 mL of a 1:100,000 dilution) once or twice a week. The dose is gradually increased over several months.
• Maintenance Phase: Once the 'top dose' is reached, the patient receives a consistent volume (typically 0.5 mL of a 1:100 or 1:10 w/v concentrate) every 2 to 4 weeks.

Thuja Occidentalis Whole may be used in children, but extreme caution is required.

• Age Considerations: Testing is generally avoided in infants under 6 months of age unless absolutely necessary. For children, the procedure is the same as for adults, but the number of simultaneous tests may be limited to reduce the total allergen load and the risk of a systemic reaction.
• Dosing: Pediatric doses for immunotherapy are often the same as adult doses, as the goal is to modify the immune system's response regardless of body weight. However, the 'build-up' phase may be slower in highly sensitive children.

Renal Impairment

No specific dosage adjustments are required for patients with kidney disease, as the extract is not cleared primarily by the kidneys in a manner that affects its safety profile. However, the patient's overall health should be stable before testing.

Hepatic Impairment

No adjustments are needed for liver impairment. The metabolism of allergenic proteins occurs locally and via the lymphatic system, bypassing the liver's primary metabolic pathways.

Elderly Patients

Elderly patients may have reduced skin reactivity (delayed or smaller wheal/flare), which can lead to false-negative results. Healthcare providers may need to adjust the interpretation of the test rather than the dose itself. Furthermore, elderly patients on beta-blockers for heart conditions are at higher risk if a reaction occurs.

Thuja Occidentalis Whole is never self-administered by the patient at home. It must be administered in a clinical setting (such as an allergist's office).

• Preparation: The skin site is cleaned with alcohol.
• Observation: After the extract is applied or injected, the patient must remain in the clinic for at least 30 minutes. This is the critical window for the development of anaphylaxis.
• Storage: Vials must be stored in a refrigerator between 2°C and 8°C (36°F and 46°F). Freezing the extract will denature the proteins and make it ineffective.

In the context of immunotherapy:

• If a dose is missed by a few days, the schedule usually continues as planned.
• If a dose is missed by more than 1-2 weeks, the healthcare provider may need to reduce the next dose to ensure safety, as the patient’s tolerance may have decreased during the gap.

An 'overdose' in this context refers to the administration of too much allergen, leading to a systemic reaction.

• Signs: Hives (urticaria) all over the body, swelling of the throat (angioedema), wheezing, shortness of breath, rapid heart rate, or a drop in blood pressure (fainting).
• Emergency Measures: Immediate administration of Epinephrine (EpiPen) is required, followed by antihistamines, corticosteroids, and emergency room observation.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to use this product without direct medical supervision.

The most common side effects of Thuja Occidentalis Whole are localized to the site of administration. These are often expected as part of the diagnostic process.

• Local Wheal and Flare: A raised, itchy bump and surrounding redness at the injection site. This typically appears within 15-20 minutes and resolves within a few hours.
• Pruritus (Itching): Intense itching at the site of the test.
• Local Swelling: Some patients may experience 'delayed local reactions' where the arm swells significantly several hours after an immunotherapy injection. This can be managed with ice packs and over-the-counter pain relievers.

• Fatigue: Some patients feel unusually tired for several hours after receiving an allergen injection.
• Headache: A mild to moderate headache may occur following testing or treatment.
• Nasal Congestion: A slight 'flare-up' of hay fever symptoms, such as sneezing or a runny nose, as the immune system reacts to the extract.

• Generalized Urticaria: Hives appearing on parts of the body far away from the injection site.
• Syncope (Fainting): Often a vasovagal response to the needle, but must be distinguished from anaphylactic shock.
• Persistent Lymphadenopathy: Swelling of the lymph nodes near the injection site that lasts for several days.

> Warning: Stop the administration process and call for emergency help immediately if you experience any of these symptoms of anaphylaxis:

• Respiratory Distress: Difficulty breathing, wheezing, or a feeling of 'tightness' in the chest or throat.
• Angioedema: Swelling of the tongue, lips, or face that may obstruct the airway.
• Hypotension: A sudden, severe drop in blood pressure, which may feel like extreme dizziness or 'blacking out.'
• Gastrointestinal Distress: Sudden, severe abdominal cramping, vomiting, or diarrhea occurring immediately after the injection.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

When used correctly for immunotherapy, Thuja Occidentalis Whole is generally safe for long-term use (3 to 5 years). There is no evidence that long-term use causes organ damage or increases the risk of cancer. The primary long-term 'effect' is the desired reduction in allergy symptoms. However, some patients may develop 'granulomas' (small, firm bumps under the skin) at the sites of repeated injections over several years.

While Thuja Occidentalis Whole may not have a specific 'Black Box' for every brand, the FDA requires a general Boxed Warning for all allergenic extracts regarding the risk of severe systemic reactions.

Summary of Warning: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients must be observed for at least 30 minutes in a facility equipped with emergency supplies (epinephrine, oxygen, IV fluids). Patients with unstable asthma or those taking beta-blockers are at increased risk of complications.

Report any unusual symptoms or delayed reactions (occurring hours after you leave the clinic) to your healthcare provider immediately.

Thuja Occidentalis Whole is a potent biological substance. It is not a medication for self-treatment of symptoms but a tool for diagnosis and immune modification. The most critical safety factor is that it must only be administered by trained personnel in a medical setting. Patients should be in their baseline state of health; if you are currently suffering from an acute asthma flare or a severe infection, testing or treatment should be postponed.

No specific FDA black box warning exists for Thuja Occidentalis Whole as a unique entity, but it falls under the mandatory Boxed Warning for all Allergenic Extracts. This warning emphasizes that:

1. 1Anaphylaxis may occur even in patients who have previously tolerated the extract.
2. 2Injections must be given subcutaneously (under the skin), never intravenously (into a vein).
3. 3Medical facilities must have 'crash carts' and trained staff ready to perform intubation or administer emergency medications.

• Allergic Reactions / Anaphylaxis Risk: This is the primary risk. Patients with a history of severe reactions to cedar or other conifers must be approached with extreme caution, starting with the highest possible dilutions.
• Asthma Status: Patients with uncontrolled or severe asthma are at a significantly higher risk for a fatal reaction to allergenic extracts. Lung function (FEV1) should be assessed before administration in asthmatic patients.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine, making an allergic reaction much harder to treat.
• ACE Inhibitor Use: Some evidence suggests that ACE inhibitors (for blood pressure) may increase the risk or severity of systemic reactions to immunotherapy.

• Pre-Injection Check: The healthcare provider will ask if you feel well and if you had any reaction to the previous dose.
• Post-Injection Observation: A mandatory 30-minute wait in the clinic is standard protocol.
• Peak Flow Meter: Asthmatic patients may be asked to use a peak flow meter before and after the injection to ensure their airway is not narrowing.

Generally, Thuja Occidentalis Whole does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.

Alcohol should be avoided for several hours before and after an injection. Alcohol causes vasodilation (widening of blood vessels), which can potentially speed up the absorption of the allergen or mask the early signs of a systemic reaction.

If a patient experiences a severe systemic reaction, the healthcare provider may decide to discontinue Thuja Occidentalis Whole immunotherapy permanently. There is no 'withdrawal' syndrome associated with stopping allergenic extracts, but the patient's original allergy symptoms will likely return over time.

> Important: Discuss all your medical conditions, especially respiratory or heart issues, with your healthcare provider before starting Thuja Occidentalis Whole.

There are few absolute contraindications for drug combinations, but the following are considered highly dangerous:

• Beta-Blockers (Non-selective and Selective): Drugs like Propranolol, Atenolol, or Timolol (including eye drops). Clinical Consequence: If the patient has an anaphylactic reaction to Thuja Occidentalis Whole, the beta-blocker will prevent epinephrine from working, potentially leading to death. Management: Patients must usually be switched to an alternative blood pressure medication before starting immunotherapy.

• ACE Inhibitors: Drugs like Lisinopril or Enalapril. Clinical Consequence: May increase the risk of severe systemic reactions. Management: Close monitoring; some allergists recommend temporary discontinuation during the build-up phase.
• MAO Inhibitors: Certain older antidepressants. Clinical Consequence: Can potentiate the effects of epinephrine if it needs to be administered for a reaction, leading to a hypertensive crisis (dangerously high blood pressure).

• Antihistamines: Drugs like Cetirizine (Zyrtec), Loratadine (Claritin), or Diphenhydramine (Benadryl). Clinical Consequence: These drugs suppress the skin's response to the allergen. Management: Patients must stop taking antihistamines for 3 to 7 days before diagnostic skin testing to avoid 'false negative' results.
• Systemic Corticosteroids: Prednisone or Methylprednisolone. Clinical Consequence: Long-term use can suppress the immune response, making the skin test less accurate.
• Tricyclic Antidepressants (TCAs): Like Amitriptyline. Similar to MAOIs, these can interfere with the body's response to emergency medications.

• Alcohol: As mentioned, alcohol can increase blood flow to the skin and potentially exacerbate a reaction. Avoid alcohol on the day of testing or treatment.
• Heavy Meals: Avoid very large, high-fat meals immediately before an injection, as gastrointestinal symptoms from a meal could be confused with the early signs of anaphylaxis.

• St. John's Wort: May theoretically affect the metabolism of other medications used during an emergency.
• Licorice Root: Can affect blood pressure and electrolyte balance, potentially complicating the management of a systemic reaction.

• Skin Testing: Thuja Occidentalis Whole is itself used for a 'test.' Any drug that affects skin reactivity (antihistamines, certain antidepressants, topical steroids at the test site) will interfere with the accuracy of the result.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter eye drops and cold medicines.

Thuja Occidentalis Whole must NEVER be used in the following circumstances:

• Previous Severe Anaphylaxis: If a patient has had a life-threatening reaction to Thuja occidentalis or its components in the past, further testing or treatment is generally considered too dangerous.
• Uncontrolled Asthma: Patients with an FEV1 (forced expiratory volume) persistently below 70% of predicted value are at an unacceptable risk for fatal bronchospasm during allergen exposure.
• Acute Infection or Fever: The immune system is already 'primed' and stressed; adding an allergen could trigger an unpredictable and severe response.
• Recent Myocardial Infarction (Heart Attack): The stress of a potential systemic reaction and the subsequent need for epinephrine could be fatal for a patient with an unstable heart.

These conditions require a careful risk-benefit analysis by the allergist:

• Pregnancy: While immunotherapy can be continued if a patient is already on a maintenance dose, it is generally not started during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen to the baby).
• Autoimmune Diseases: Conditions like Lupus or Rheumatoid Arthritis may be exacerbated by stimulating the immune system with allergenic extracts.
• Malignancy: Patients with active cancer may have altered immune responses.
• Young Children: Children under age 5 may be unable to communicate the early symptoms of a systemic reaction, making administration riskier.

Patients who are allergic to Thuja Occidentalis Whole may also react to other members of the Cupressaceae (Cypress) family, including:

• Juniper (Juniperus species)
• Cypress (Cupressus species)
• Redwood (Sequoia)

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and heart health, before prescribing or administering Thuja Occidentalis Whole.

Pregnancy Category: C. There are no adequate and well-controlled studies of Thuja Occidentalis Whole in pregnant women.

• Risk of Anaphylaxis: The primary concern is not the extract itself being toxic to the fetus, but the risk of the mother having an anaphylactic reaction. Anaphylaxis causes a drop in blood pressure and oxygen levels, which can lead to fetal distress, miscarriage, or premature labor.
• Clinical Guidance: Most allergists will not start new immunotherapy or perform skin testing during pregnancy. If a woman is already on a stable maintenance dose and is tolerating it well, the treatment may be continued, but the dose is usually not increased until after delivery.

It is not known whether the components of Thuja Occidentalis Whole are excreted in human milk. However, because these are large proteins administered in minute amounts, it is highly unlikely that they would reach the infant in significant quantities via breast milk. The main risk remains a systemic reaction in the mother. Breastfeeding is generally considered safe for women receiving maintenance immunotherapy.

Thuja Occidentalis Whole is used in children, but the clinical approach is specialized.

• Safety: Children are at the same risk for anaphylaxis as adults. Because they may not be able to describe 'throat tightness' or 'impending doom,' they must be monitored very closely by experienced pediatric allergy staff.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development.
• Indications: It is used for children with significant allergic rhinitis or asthma that is not well-controlled by environmental avoidance and standard medications.

In patients over 65, several factors must be considered:

• Reduced Skin Reactivity: The 'wheal and flare' response diminishes with age, which can lead to under-diagnosis of cedar allergy.
• Co-morbidities: Elderly patients are more likely to have underlying heart disease or COPD, making them less able to survive a systemic allergic reaction.
• Polypharmacy: The high prevalence of beta-blocker and ACE inhibitor use in this age group significantly complicates the safety profile of Thuja Occidentalis Whole.

There are no specific restrictions for patients with renal impairment. The extract is not a systemic chemical drug that requires kidney filtration for clearance. However, patients on dialysis should have their immunotherapy scheduled on non-dialysis days to ensure they are at their physiological baseline.

No adjustments are required for patients with liver disease. The processing of the allergenic proteins is an immunological process, not a hepatic metabolic process.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or start new medications for heart or kidney health.

Thuja Occidentalis Whole acts as a specific antigen (a substance that triggers an immune response). In sensitized individuals, the proteins in the extract cross-link IgE antibodies bound to the high-affinity receptor (FcεRI) on the surface of mast cells and basophils. This cross-linking triggers a signaling cascade involving tyrosine kinases (like Syk), leading to the release of pre-formed mediators (histamine) and the de novo synthesis of lipid mediators (leukotrienes). In immunotherapy, the mechanism shifts toward inducing 'T-cell anergy' or 'deletion' and the production of Regulatory T-cells (Tregs) that secrete IL-10, which suppresses the allergic inflammation.

• Dose-Response: There is a clear dose-response relationship in skin testing; higher concentrations of the extract produce larger wheals.
• Onset: The immediate (Type I) reaction occurs within 15-20 minutes.
• Late-Phase Reaction: Some patients may experience a late-phase reaction 4-8 hours later, characterized by more diffuse swelling and redness, mediated by recruited eosinophils and Th2 cells.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intended for local effect) |

| Protein Binding | N/A |

| Half-life | Minutes to hours (localized) |

| Tmax | 15-20 minutes (for skin reaction) |

| Metabolism | Proteolysis (local and lymphatic) |

| Excretion | Lymphatic clearance |

• Composition: A complex mixture of proteins, glycoproteins (carbohydrate-protein complexes), and terpenes (such as thujone, though thujone is usually minimized in allergenic extracts compared to essential oils).
• Solubility: Soluble in aqueous solutions and glycerol-saline mixtures.
• Molecular Weight: Ranges from 10 kDa to over 100 kDa for various allergenic proteins.

Thuja Occidentalis Whole belongs to the class of Allergenic Extracts. It is specifically grouped under non-standardized extracts because there is no nationally recognized standard of potency for Thuja occidentalis in the United States, unlike grasses or ragweed which have standardized BAU (Bioequivalent Allergy Units).